Alarice C Lowe
Overview
Explore the profile of Alarice C Lowe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saylor P, Otani K, Balza R, Ukleja J, Pleskow H, Fisher R, et al.
JCO Precis Oncol
. 2024 Feb;
8:e2300230.
PMID: 38354328
Purpose: Radium-223 improves overall survival (OS) and reduces skeletal events in patients with bone metastatic castration-resistant prostate cancer (CRPC), but relevant biomarkers are lacking. We evaluated automated bone scan index...
2.
Zhu Y, Moore S, Wang A, George E, Allard G, Libert D, et al.
Cancer Cytopathol
. 2023 Apr;
131(8):507-515.
PMID: 37069606
Background: Epithelial cell adhesion molecule (EpCAM) is frequently used to distinguish carcinoma from background mesothelial cells during cytologic examination of body cavity fluids. Previously, the authors identified one malignant mesothelioma...
3.
Zhu Y, Wang A, Allard G, Nordberg J, Nair R, Kunder C, et al.
Cancer Cytopathol
. 2022 Jun;
130(10):771-782.
PMID: 35731106
Background: Effective cancer treatment relies on precision diagnostics. In cytology, an accurate diagnosis facilitates the determination of proper therapeutics for patients with cancer. Previously, the authors developed a multiplexed immunofluorescent...
4.
Zhu Y, Allard G, Ericson N, George T, Kunder C, Lowe A
Cancer Cytopathol
. 2021 Jun;
129(11):893-906.
PMID: 34171181
Background: Cancer is a leading cause of death worldwide, and patients may have advanced disease when diagnosed. Targeted therapies guided by molecular subtyping of cancer can benefit patients significantly. Pleural...
5.
Harris E, Huang J, Carroll E, Lowe A, Chau N, Rabinowits G, et al.
Laryngoscope Investig Otolaryngol
. 2020 Dec;
5(6):1063-1069.
PMID: 33364395
Background: Circulating tumors cells (CTCs) are considered an early step towards metastasis and have been linked to poor prognosis in several types of cancer. CTCs in squamous cell carcinoma of...
6.
Lim M, Park J, Lowe A, Jeong H, Lee S, Park H, et al.
Theranostics
. 2020 May;
10(12):5181-5194.
PMID: 32373206
: Unlike traditional biopsy, liquid biopsy, which is a largely non-invasive diagnostic and monitoring tool, can be performed more frequently to better track tumors and mutations over time and to...
7.
Wong K, Jo V, Lowe A, Faquin W, Renshaw A, Shah A, et al.
Cancer Cytopathol
. 2019 Nov;
128(1):68-75.
PMID: 31751003
Background: Hürthle cell metaplasia is common in hyperplastic nodules, particularly within the setting of lymphocytic thyroiditis (LT). The Bethesda System for Reporting Thyroid Cytopathology indicates that it is acceptable to...
8.
Torre M, Lee E, Chukwueke U, Nayak L, Cibas E, Lowe A
J Am Soc Cytopathol
. 2019 Oct;
9(1):45-54.
PMID: 31606331
Introduction: Dissemination of tumor to the leptomeninges, subarachnoid space, and cerebrospinal fluid (CSF) is termed leptomeningeal metastasis (LM) and occurs in approximately 5% of patients with solid tumors. LM is...
9.
Vivero M, Wang C, Jo V, Hollowell M, Cibas E, Lindeman N, et al.
J Am Soc Cytopathol
. 2019 May;
6(1):16-23.
PMID: 31042629
Introduction: This study constitutes the first systematic comparison of molecular results between different cytology preparations in patients with lung adenocarcinoma undergoing testing for EGFR, KRAS, and BRAF mutations. Materials And...
10.
Sundling K, Lowe A
Adv Anat Pathol
. 2018 Oct;
26(1):56-63.
PMID: 30325755
Circulating tumor cells (CTCs) have long been assumed to be the substrate of cancer metastasis. However, only in recent years have we begun to leverage the potential of CTCs found...